Astilbin Suppresses Acute Heart Allograft Rejection by Inhibiting Maturation and Function of Dendritic Cells in Mice

作者：Zou, S.; Shen, X.; Tang, Y.; Fu, Z.; Zheng, Q.; Wang, Q.^*

来源：Transplantation Proceedings, 2010, 42(9): 3798-3802.

DOI：10.1016/j.transproceed.2010.06.031

• ACTIVATION
• TRANSPLANTATION
• KINASE
• P38

The effect of astilbin on acute graft rejection was investigated in C57BL/6 mice carrying BALB/c hearts heterotopically transplanted into the neck vessels. Daily treatment with astilbin (50, 125, or 250 mg/kg intraperitoneally) significantly prolonged the survival of grafts in a dose-dependent manner, when cyclosporine (CsA; 5 mg/kg) was co-administered with astilbin (250 mg/kg), there was more potent immunosuppression than that solely achieved by 20 mg/kg CsA. Addition of 10 mg/mL astilbin significantly inhibited the proliferation and activation of T cells, as determined by H-3 thymidine deoxyribose uptake, Western blots for nuclear factor kappa B and p38, and 1-way mixed lymphocyte reactions (MLR). Mature and antigen-presenting functions of dendritic cells (DCs) also were inhibited by astilbin (10 mg/mL), as determined by morphologic observations, flow cytometry, and MLR. These observations suggested that astilbin is a potential candidate for immunosuppressive therapy after heart engraftment. Inhibiting the maturation and antigen-presenting function of DCs and thus preventing T-cells activation is a possible mechanism underlying its inhibitory effects on acute heart allograft rejection.

• 出版日期2010-11
• 单位上海交通大学; 中国人民解放军第二军医大学; 天津市中医药研究院附属医院